MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

19.37 7.97

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16

Max

19.6

Galvenie mērījumi

By Trading Economics

Ienākumi

-681K

Pārdošana

17M

P/E

Sektora vidējais

48.528

87.826

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

-3.9

Darbinieki

212

EBITDA

-79M

-74M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+5.26% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.26%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

19M

387M

Iepriekšējā atvēršanas cena

11.4

Iepriekšējā slēgšanas cena

19.37

Ziņu noskaņojums

By Acuity

9%

91%

11 / 372 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. janv. 23:08 UTC

Iegādes, apvienošanās, pārņemšana

Rio Tinto, Glencore in Talks to Form World's Biggest Miner -- 3rd Update

2026. g. 8. janv. 21:39 UTC

Iegādes, apvienošanās, pārņemšana

Glencore, Rio Tinto Restart Merger Talks -- 2nd Update

2026. g. 8. janv. 20:54 UTC

Iegādes, apvienošanās, pārņemšana

Glencore, Rio Tinto Restart Merger Talks -- Update

2026. g. 8. janv. 20:44 UTC

Iegādes, apvienošanās, pārņemšana

Glencore, Rio Tinto Restart Merger Talks

2026. g. 8. janv. 17:05 UTC

Iegādes, apvienošanās, pārņemšana

Chinese Anta Sports Products Offers to Buy Pinault Family's Stake in Puma, Reuters Says, Citing Unnamed Sources

2026. g. 8. janv. 16:43 UTC

Galvenie tirgus virzītāji

Babcock & Wilcox Shares Rise on Siemens Deal for Data Center Project

2026. g. 8. janv. 23:44 UTC

Tirgus saruna

Nikkei May Rise on Weaker Yen -- Market Talk

2026. g. 8. janv. 23:37 UTC

Tirgus saruna

Gold Steady, Underpinned by Geopolitical Risks -- Market Talk

2026. g. 8. janv. 22:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 8. janv. 22:42 UTC

Tirgus saruna

RBA Still Battling a Troubling Inflation Outlook, Says TD -- Market Talk

2026. g. 8. janv. 22:30 UTC

Iegādes, apvienošanās, pārņemšana

Glencore, Rio Tinto Confirm Early Merger Talks -- Barrons.com

2026. g. 8. janv. 21:53 UTC

Peļņas

These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

2026. g. 8. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 8. janv. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 8. janv. 21:10 UTC

Iegādes, apvienošanās, pārņemšana

Rio Tinto Says Current Expectation That Any Deal Would Involve Buying Glencore Via Scheme of Arrangement

2026. g. 8. janv. 21:09 UTC

Tirgus saruna

Oil Rises As Trump Said to Back Russia Sanctions Bill -- Market Talk

2026. g. 8. janv. 21:09 UTC

Iegādes, apvienošanās, pārņemšana

Rio Tinto Confirms in Talks With Glencore Over Possible Merger

2026. g. 8. janv. 20:21 UTC

Tirgus saruna

U.S. Natural Gas Futures Down Despite Inventory Draw -- Market Talk

2026. g. 8. janv. 19:44 UTC

Tirgus saruna

Gold's Shine Masks Deep Drops in Canada Steel, Aluminum Exports -- Market Talk

2026. g. 8. janv. 18:50 UTC

Tirgus saruna

Mexico's Industrial Production Seen Lower in November -- Market Talk

2026. g. 8. janv. 17:48 UTC

Peļņas

These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

2026. g. 8. janv. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 8. janv. 17:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 8. janv. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 8. janv. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 8. janv. 16:45 UTC

Tirgus saruna

Goldman Lifts 1H LME Copper Forecast -- Market Talk

2026. g. 8. janv. 16:03 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 8. janv. 16:03 UTC

Tirgus saruna

Currency Markets Could Be Underpricing Medium-Term Risks -- Market Talk

2026. g. 8. janv. 16:02 UTC

Tirgus saruna

U.S. Natural Gas Inventories Fall As Expected -- Market Talk

2026. g. 8. janv. 15:23 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Defends Its Hostile Bid for Warner -- Update

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

5.26% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD  5.26%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

11 / 372 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat